A supply line into Türkiye and the CIS for medical device manufacturers.
In Türkiye and the CIS, a device’s registration, import, field sales and collections all run through our own team. The licence is held in Alzey’s name, and vigilance reporting from the field stays our responsibility. The work doesn’t end when a device reaches the shelf; it runs on until it sells.
We are the Master Distributor for the Allurion Swallowable Gastric Balloon and Allurion Virtual Care Suite (VCS) lines across Türkiye and the CIS, and the registration holder and importer in Türkiye — running regulatory affairs, operations and growth under one team.
A manufacturer entering this market has two options: buy a market-entry report, or work with an operator who runs the job on the ground. We’re the operator; from the registration file to collections, the chain is ours to answer for.
We can’t take every device. The physician profile of our network and our field rhythm work in specific categories; outside them we are probably the wrong partner, and we will say so in the first call.
The lines we represent today, and our capacity in adjacent categories, are recorded on the portfolio page.
Which lines we can take.
- Obesity and metabolic devices
- Our core line; the network is built around this category.
- Bariatric and endoscopic devices and consumables
- Lines that reach the same physician and the same procedure setting; our field team keeps the same counterpart.
- Body contouring and aesthetic technologies
- The second device line for centres that carry the patient on after obesity treatment.
- Metabolic monitoring and digital health hardware
- Hardware that sits inside follow-up programmes; the digital side already runs on our own systems.
- Premium device lines aimed at medical travel
- Lines for centres that receive patients from abroad. We run that channel separately.
- Innovative medical solutions
- Devices in categories Türkiye has not defined yet, where clinical adoption and patient demand have to be built together. Building the category is part of the operation.
Operating regions
Türkiye · Kazakhstan · Uzbekistan · Georgia · Azerbaijan
How the B2B2C model works.
A standard distribution agreement has two sides. The operation we run has three, and all three have to win on the same transaction: you sell your device, the clinic finds its patient, the patient gets access to treatment.
On the B2B side we build, train and manage the clinic network; on the B2C side we run the patient-facing surfaces, the ad accounts and the intake line with our own team. A single CRM and a single field rhythm join the two layers.
B2B · product and trade flow
- Manufacturer
- Alzey
- Authorised centre
- Patient
B2C · demand flow
- Alzey
- Patient demand
- Authorised centre
Medical distribution in Türkiye usually stops at the B2B side; building patient demand is left to the manufacturer or to the clinic. A distribution partner that also runs the demand layer is uncommon in this market.
The route a device takes.
The ten steps below run from the registration file to the collected receivable, all on our side of the agreement.
Registration
The registration file
The file sits with us: we prepare it, submit it and answer for it.
TİTCK and ÜTS
The TİTCK licence and the ÜTS record — Türkiye’s device-tracking registry — are both held in Alzey’s name.
Import and buffer stock
Import and customs
We import in our own name; customs and freight run through licensed service providers, while the paperwork and the responsibility stay with us.
Buffer stock
Buffer stock sits in our own warehouse, so an authorised centre never runs dry.
Authorised centre
The authorised centre
The product moves only to authorised centres.
Physician training
Physicians at authorised centres go through the manufacturer’s certification programme.
Demand and sale
The demand channel
We build demand through channels we own and route the patient flow to authorised centres.
The sale
Our field team runs the sell-through; orders, delivery and after-sales sit with one team.
Collections and vigilance
Receivables and collections
We carry the credit. Channel credit risk sits with us: you deal with one counterparty, and collections in the field are ours to follow.
Vigilance
Vigilance and adverse-event reporting continue under our responsibility as authorised distributor.
One agreement, one accountable counterparty — from licence to collections.
What sits inside a registration file.
A TİTCK file is eight consecutive pieces of work, each with its own paperwork, owner and calendar.
Regulatory feasibility and classification assessment
We establish which class the device falls into in Türkiye and which pathway it has to follow, before a file is opened.
Labelling and Turkish IFU compliance check
Labels, packaging and the instructions for use are prepared in Turkish, with the content the regulation requires.
Technical file compilation and gap analysis
We compile the manufacturer’s technical documentation and list what is missing on one page, ahead of submission.
TİTCK submission and official follow-up
The application is filed in Alzey’s name; correspondence with the authority and the deadlines are ours to manage.
ÜTS registration and product numbering
The product is entered into ÜTS, with singular numbering and notifications running off that record.
Promotional and advertising material compliance review
Everything that reaches the field is reviewed against Turkish advertising rules and the manufacturer’s own brand controls.
Change notifications (minor/major) and renewals
When the product or the file changes we notify it, and the licence renewal is filed on time.
Vigilance and adverse-event reporting
A signal from the field is recorded, reported to the authority and coordinated with the manufacturer.
None of this is a new service line: it is the work every file already goes through, named. All eight stay on one desk, and none of them travels back to yours.
Three columns, one operation.
Regulatory affairs, operations and growth: on the ground, the three columns work as seven lines. Each comes with its proof.
- Registration and market access
- TİTCK licensing and ÜTS registration run in Alzey’s name in Türkiye. In Kazakhstan (NCEDMD/EAEU), Uzbekistan, Georgia (RAMA) and Azerbaijan our distribution network is active.
- Import, logistics and stock
- From EXW onwards the chain is ours: import, warehousing and delivery to the centre, with buffer stock underwriting the line.
- Commercial execution
- Sales run through our own field team and a CRM that holds our registered clinics. Receivables management and collections stay with us.
- Demand generation
- The demand channel is ours: patient-facing site, ad accounts and WhatsApp line. The infrastructure is built; the organic engine is not yet fully running.
- Physician training and KOL
- Training runs through the manufacturer’s certification programme; congress presence and KOL relationships sit on the same line.
- Quality and compliance
- Vigilance, adverse-event reporting, marketing compliance (Red/Amber/Green) and data protection live inside the daily operation; the detail sits on the Quality & Compliance page.
- Caucasus and Central Asia expansion
- The same model runs into neighbouring markets through our regional distribution network. In Kazakhstan and Uzbekistan the operation is active.
What the network is made of.
“A hundred centres” tells a manufacturer very little on its own. Your question is whether those centres can sell your device.
The 100+ centres we work with are a mix of those five channels. The spine of the network is clinics and bariatric physicians working in obesity and metabolic care; physicians at authorised centres go through the manufacturer’s certification programme. A field team of 5+ people carries this network.
Medical-travel agencies are a distinct channel inside that network. Türkiye draws a strong inbound patient flow for aesthetic and surgical procedures, and that flow makes demand for premium devices partly independent of the local patient economy.
The commercial stack runs on software we wrote.
Underneath the field operation runs software we built ourselves: the clinic network, a patient’s first contact, receivables, collections and conversion all sit in the same system.
Contact layer
- WhatsApp lead line
- Patient-facing surfaces
- Ad accounts
Operating layer
- Our own clinic CRM
- Network segmentation
- Field visit rhythm
- Quotation generation
Analytics layer
- Receivables and collections analytics
- Conversion optimisation tooling
- Process automation and reporting
The schematic above is deliberately abstract: system screens, clinic names and commercial data stay inside.
The layer does more than keep records: network segmentation, the field-visit plan and proposal preparation are derived from the same data. When a process has to change, our own team changes it.
We build the sales routine together with the clinic.
Regulatory affairs and operations have ten steps. Growth has its own, and training the physician is not enough on its own.
- 01
Clinic segmentation and field rhythm
We segment the network by patient profile and capacity, then set a visit and follow-up rhythm for each segment.
Segmentation is more than geography: the physician's academic profile, the clinic's capacity and its patient source all change what a visit is for. With an academic unit the agenda is literature and congress work; with a volume-driven centre it is capacity and patient flow. The field team follows each segment's own rhythm.
- 02
Physician training and the manufacturer’s certification programme
Training runs to certification; congress work and KOL relationships sit on the same line.
Training content comes from the manufacturer's official programme; certification is a precondition of authorised-centre status and sits on record. Congress sponsorship and scientific-session coverage continue the same line.
- 03
Front-desk conversion programme
The clinic’s first contact is the front desk. We put a written frame around how calls are answered, how objections are handled and how conversion is measured.
Incoming calls are logged and conversion to consultation is measured; a prepared objection library covers the questions that come up. A weekly rhythm meeting runs with the front desk and a monthly review with the physician, so conversion is tracked rather than assumed.
- 04
Demand channel and patient routing
Patient flow from our own channels is routed to the authorised centre that can actually take that patient.
Incoming demand lands in one pool and routing follows suitability and geography; carrying the patient to the right centre is as much the job as generating the demand.
- 05
ROI modelled on the clinic’s own numbers
Return is modelled on the clinic’s own patient volume, capacity and cost base. The sheet on the table is the clinic’s sheet.
We bring the template and the method; we don't set the target. The decision is made on a sheet built from the clinic's own data.
The marketing, patient-flow coordination and sales training programmes we have delivered at centres offering 360-degree obesity care now number more than a hundred.
You won’t find a conversion rate, a patient count or a sales figure on this page; those numbers belong to the clinic and stay there.
The line we run today.
The pattern set out above runs today on the Allurion line: registration, import, the authorised-centre network, field sales and collections sit with the same team. The scope of that authority, and the dates behind the field continuity, are recorded below.
Allurion Technologies Inc. — Master Distributor for the Swallowable Gastric Balloon and VCS lines across Türkiye and the CIS. Import, stocking, distribution to authorised centres and the downstream commercial work all run under this authority. Alzey was founded in 2024; field continuity on the product line dates back to 2021. The dated regulatory record lives on the Allurion Türkiye page.
What we distribute.
The Allurion Program consists of the Smart Capsule, the Smart Scale, a mobile app and six months of nutritional follow-up. The device holds FDA PMA Class III full approval (23.02.2026); on the CE side, CE 0123 (TÜV SÜD) — Article 120 transition regime.
The programme definition is structural; the dated summary of regulatory status sits in the band below.
Regulatory status
- FDA
- PMA Class III full approval· 23.02.2026
- CE
- CE 0123 (TÜV SÜD) — Article 120 transition regime
- Türkiye
- TİTCK licensed · ÜTS registered
Regulatory status may change; consult official TİTCK and FDA records for the current position.
Let’s talk about bringing your device into this market.
This page is written for device manufacturers and their business-development teams. Physicians and clinics looking for programme information will find it on allurion.alzeypartners.co. It shares no clinical-efficacy or weight figures; it is a corporate statement, not marketing.
This page was last reviewed on 21.08.2026.